

INSTRUCTIONS FOR AUTHORS

Cancer Research is the official journal of the American Association for Cancer Research, Inc., and is devoted to the publication of significant, original research in all the subfields of cancer research, including: biochemistry; biophysics; cell biology; chemical, physical, and viral carcinogenesis and mutagenesis; clinical investigations; endocrinology; epidemiology; experimental pathology; immunology; molecular biology and genetics; physiology; preclinical pharmacology and experimental therapeutics (including biological therapy); radiobiology and radiotherapy; and virology.

Only those papers reporting results of novel, timely, and significant studies and meeting high standards of scientific merit will be accepted. Papers are stringently reviewed and are published within a maximum of 90 days of acceptance.

CATEGORIES OF PUBLICATION

The following types of material will be considered for publication:

- (1) Papers containing results of original experimental, clinical, or epidemiological studies that are sufficiently well documented as to be acceptable to the critical reader.
- (2) Advances in Brief, which are short, definitive reports of highly significant and timely findings in the field. These submissions receive rapid reviews and, if acceptable, are published within 2 to 3 months of receipt. They should be approximately 3 printed pages in length (about 12 double-spaced typescript pages), containing an Abstract of about 100 words, a one-paragraph Introduction, an abbreviated Materials and Methods section, Results and Discussion sections (which may be combined), a maximum of 20 references, and no more than 4 items for the display of data (any combination of figures and tables).
- (3) Perspectives in Cancer Research, which are invited articles analyzing either very active or undeveloped areas of research and presenting fresh insights and personal viewpoints on where research in that area may or should be heading.
- (4) Concise reviews on subjects of importance to cancer researchers. Authors of unsolicited reviews should submit an outline of the proposed article for approval by the Editorial Board. If submission of the complete article is encouraged, the review will be given particularly stringent editorial evaluation before acceptance.
- (5) Public Issues, which are brief reports on topics of interest to cancer researchers and the general public; these might include articles on funding for cancer research, training in the field, public education, etc.
- (6) Letters to the Editor, which consist of correspondence about manuscripts published in the Journal. Correspondence which concerns articles not published in *Cancer Research* will not be considered.
- (7) Brief reports of meetings, symposia, and conferences on cancer research. These should comprise no more than 3 printed pages (approximately 12 double-spaced typescript pages) and include a statement of the purpose(s) of the meeting, an integrated summary of the findings presented, and recommendations for future research. The names and affiliations of key speakers may be included if space is available.
- (8) Proceedings of symposia, published as external supplements to the Journal (*Supplements to Cancer Research*), the full expenses of which are assumed by the sponsoring agency. These proceedings are accepted for publication at the discretion of the Editor-in-Chief, based on the importance of the topic covered, the scope of the presentations, and the participants at the meeting.
- (9) Brief announcements of scientific meetings and of courses in cancer-related biomedical science of interest to our readers. These should be submitted at least 3 months prior to the expected month of issue.
- (10) Brief listings of recent deaths of distinguished contributors to the field of cancer research.

EDITORIAL POLICIES

Submission of a manuscript to *Cancer Research* implies that the author(s) of the paper understand and accept the policies of the Journal as detailed in these "Instructions for Authors."

When a manuscript is received for consideration, the Editors assume that neither the submitted paper nor any similar paper, other than an abstract or preliminary communication, has been or will be submitted for publication or published elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission and content.

For revised manuscripts, if an author is deleted or a new author is added, it is the responsibility of the corresponding author to provide the Publications Department with written documentation at the time of resubmission that the authors involved are aware of and agree to the changes in authorship. *Cancer Research* accepts no responsibility for such changes.

The Journal maintains an international editorial board of Associate Editors with broad expertise in all subfields of basic and clinical cancer research. These Associate Editors, along with a large body of outside reviewers, provide fair and thorough evaluations of papers submitted to *Cancer Research*. Submission of a manuscript implies acceptance of the strict policy of the Journal that under no circumstances will the identities of the Associate Editors and reviewers be revealed. Every effort is made to render editorial decisions promptly, consistent with thoroughness of review. Inquiries regarding the status of manuscripts should be submitted in writing.

Collect telephone calls from authors cannot be accepted.

SUBMISSION AND PUBLICATION FEES

A nonrefundable submission fee of \$75 is assessed for each manuscript and must be paid regardless of the decision rendered on the paper. A check (drawn on a U.S. bank) or purchase order in U.S. currency, payable to the American Association for Cancer Research, Inc., must accompany the manuscript. If a purchase order must precede payment by an institution, it is the author's responsibility to ensure that the purchase order is followed by payment of the fee.

If an author resubmits a manuscript that our Editors previously found unacceptable for publication, it is Journal policy to consider it a new submission, assign it a new manuscript number, and charge the author another \$75 submission fee. The covering letter accompanying such submissions should indicate that the paper is a resubmission of a manuscript previously declined for publication and give the number of the earlier submission.

A page charge of \$65 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to the Editor-in-Chief at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

PROCEDURES FOR SUBMISSION

Contributions should be addressed to Dr. Carlo M. Croce, Editor-in-Chief, *Cancer Research*, American Association for Cancer Research, Inc., Public Ledger Bldg., 620 Chestnut Street, Suite 816, Philadelphia, PA 19106-3483. They should be submitted by an author, preferably the senior author, who should indicate in a covering letter:

- (1) that the paper should be considered for publication in *Cancer Research*;
- (2) the exact address to which all related correspondence should be sent and telephone and FAX numbers at which the author can be reached;
- (3) that authorization has been given to use any information conveyed by either personal communication or release of unpublished experimental data;
- (4) the salient and novel findings of the paper (in as concise a statement as possible);
- (5) which one of the following subject categories applies to the manuscript:

BASIC SCIENCES

Biochemistry and Biophysics
 Carcinogenesis
 Endocrinology
 Immunology
 Molecular Biology and Genetics
 Preclinical Pharmacology and Experimental Therapeutics
 Tumor Biology
 Virology

CLINICAL INVESTIGATIONS

Clinical Studies
 Epidemiological Studies

[Final category assignment of an article in an issue's Table of Contents is at the discretion of the Editor-in-Chief.]

Authors may suggest appropriate Associate Editors (the names of whom are listed in the front of each issue of *Cancer Research*) and reviewers to whom the manuscript could be assigned; however, final assignment is at the Editor-in-Chief's discretion.

Original submissions must include:

- (1) The author's covering letter *in duplicate* containing the above information.
- (2) *Four* copies of the manuscript and *four* sets of original illustrations. Indicate which set of original illustrations should be used by the printer in the event of publication.

We cannot guarantee that manuscripts and illustrations will be returned to the author.

- (3) Papers in press or submitted for publication which are highly relevant to the manuscript under review.

Revised manuscript submissions must include:

- (1) A covering letter *in duplicate*, clearly indicating what alterations have been made in response to the criticisms raised. Satisfactory reasons should be given for noncompliance with any of the recommendations for revision.
- (2) *Four* copies of the revised version of the manuscript, plus a red-marked copy of the manuscript indicating the changes made, and *four* sets of original illustrations.

We cannot guarantee that manuscripts and illustrations will be returned to the author.

- (3) If available, a disk of the *revised version* of the manuscript to be used for typesetting the article in the event of publication. The disk must be accompanied by a completed Disk Submission Form, which can be found in the back of each issue of *Cancer Research*. (See "Typesetting from Disks" section for further details.)

Revised manuscripts will undergo another review, if the original submission required extensive changes.

FORMAT AND STYLE

Papers should conform strictly to Journal style. A recent issue of *Cancer Research* will provide authors with assistance in the proper arrangement of papers. Manuscripts are to be written in clear, grammatical English. Papers that are not in good idiomatic English will be returned to the author without review. Laboratory slang as well as terminology and abbreviations not consistent with internationally accepted guidelines should be avoided.

For general and technical assistance in writing scientific papers, authors should refer to the following publications: *Stedman's Medical Dictionary* (Twenty-fifth Edition, 1990, The Williams & Wilkins Co., Baltimore, MD); *CBE Style Manual* (Fifth Edition, 1983, published by the Council of Biology Editors, Inc., Bethesda, MD); and *The ACS Style Guide* (First Edition, 1986, American Chemical Society, Washington, DC).

Data must be presented concisely. Large masses of data of peripheral significance to the main thesis of the investigation will not be published in *Cancer Research* but may be deposited with the National Auxiliary Publications Service, c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513; (516) 481-2300. The manuscript should contain a footnote that indicates how this ancillary material can be obtained. Such data should be submitted for review along with the manuscript.

The manuscript should be typed on 21.6- × 28-cm (8½- × 11-inch) paper with double spacing *throughout*, allowing for ample margins. Manuscripts with typing on both sides of the page will be returned to the authors. Consecutive numbering of all pages is required, with the title page as page 1. The typescript should be arranged in the following order: (a) title, (b) author(s) and complete name(s) and location(s) of institution(s) or laboratory(ies), (c) running title, (d) key words, (e) footnotes, (f) text and references, (g) tables, (h) legends for all illustrations, (i) illustrations, and (j) other material. Numbered and lettered sections in the text should be avoided. The appropriate location for each table and illustration should be indicated by marginal notes. Simple chemical formulas or mathematical equations should be presented in a form that allows their reproduction in single horizontal lines of type; more complicated mathematical formulas or chemical structures difficult to set in type should be provided in the form of India ink drawings or glossy photographs for camera-ready reproduction.

Title. Titles should be brief but informative, and limited if possible to about 100 characters. It is important for literature retrieval to include in the title the key words necessary to identify the nature of the subject

matter, including, if applicable, the species on which the work is done. Use of expressions such as "Studies on . . ." or "Observations of . . ." should be avoided, since they are not informative. Chemical formulas or abbreviations should not be used. Also, do not use Roman or Arabic numerals to designate that the paper is one in a series (*see* section below on Footnotes).

Authors and Their Affiliations. Authors are urged to include their full names, complete with first and middle names or initials. Confusion often arises in the literature when authors are identified by surname and initials only. Authors' academic degrees should not be included. The full names of institutions and subsidiary laboratories should be given, together with a useful address (including postal code). If several authors and institutions are listed on a paper, it should be clearly indicated with which department and institution each author is affiliated.

Running Title. A brief running title should be provided, not to exceed 50 characters. Running titles in the form of declarative or interrogative sentences are not acceptable.

Key Words. On the title page, provide five key words identifying the nature of the subject matter.

Footnotes. Lengthy footnotes are discouraged since the same information can in most instances be presented more effectively in the text.

Footnotes to the title page and text are to be designated consecutively with superscript Arabic numerals. A footnote to the title should contain information on financial support, including the source(s) and number(s) of the grant(s). If the paper is one of a series, a footnote to this effect may be included. Authors should also include a footnote designating to whom reprint requests should be addressed. An all-inclusive abbreviation footnote should contain a definition for every nonstandard abbreviation used in the paper.

For footnotes to tables, *see* section on Tables below.

Abstract. The abstract, to appear at the beginning of the paper, should be concise, yet indicative of the content of the paper. As abstracts are often copied directly by the secondary services, they should recapitulate in abbreviated form the purpose of the study and the experimental technique, results, and interpretations of the data. Data such as the number of test subjects and controls, strains of animals or viruses, drug dosages and routes of administration, tumor yields and latent periods, length of observation period, and magnitude of activity should be included. Vague, general statements such as "The significance of the results is discussed," or "Some physical properties were studied," are uninformative and not acceptable. All important terms relevant to the content of the paper should be incorporated into the abstract to assist indexers in the derivation of key words. Abbreviations should be kept to an absolute minimum; however, if they are needed, they must be properly identified so as to make the abstract independent of the text. Authors may wish to keep in mind that "Medline," a computerized monthly bibliography prepared by the National Library of Medicine, includes only those abstracts that contain fewer than 200 words; with very few exceptions, longer abstracts are not accessible through that service.

Introduction. It is not necessary to include all of the background literature in this section. Brief reference to the most pertinent papers generally suffices to acquaint the reader with the findings of others in the field and with the problem or question which the author's particular investigation addresses.

Materials and Methods. Explanation of the experimental methods should be brief but adequate for repetition by qualified investigators. Procedures that have been published previously should not be described in detail but merely cited in appropriate references. Only new and significant modifications of previously published procedures need complete exposition. The sources of special chemicals or preparations used should be given along with their locations [city and state (country, if foreign)].

This Journal endorses the principles embodied in the Declaration of Helsinki and expects that all investigations involving humans will have been performed in accordance with these principles. In particular, papers reporting human experimentation must include a statement that the human investigations were performed after approval by a local Human Investigations Committee and in accordance with an assurance filed with and approved by the Department of Health and Human Services, where appropriate. Also, papers reporting biomedical research involving human subjects must include a statement that informed consent was obtained from each subject or subject's guardian. A copy of the Helsinki Declaration is available from the American Medical Association, 535 N. Dearborn Street, Chicago, IL 60610.

For animal experimentation reported in this Journal, it is expected that investigators will have observed the *Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education* issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research.

Results. This section should include a concise textual description of the data presented in tables and illustrations. Excessive elaboration of data already given in tables and illustrations should be avoided. The Results and Discussion sections should be combined if, by so doing, space is saved or the logical sequence of the material is improved.

Discussion. In this section, the data should be interpreted concisely without repeating material already presented in the Results section. Speculation is permissible, but it must be well founded.

References. *Number references in the order of their first mention in the text; cite only the number assigned to the reference.* References should be typed in double-spaced form to facilitate copy editing. The bibliography should be limited to only those citations essential to the author's presentation. When comprehensive review articles are available, they are preferred to many separate references.

Before submission of the paper authors should verify the accuracy of all references and should check that all references have been cited in the text. Examples of the two most common types of Journal references are:

Saylors, R. L., III, Sidransky, D., Friedman, H. S., Bigner, S. H., Bigner, D. D., Vogelstein, B., and Brodeur, G. M. Infrequent *p53* gene mutations in medulloblastomas. *Cancer Res.* 51: 4721-4723, 1991.

Yuspa, S. H., Hennings, H., Roop, D., Strickland, J., and Greenhalgh, D. A. Genes and mechanisms involved in malignant conversion. In: C. C. Harris and L. A. Liotta (eds.), *Genetic Mechanisms in Carcinogenesis and Tumor Progression*, pp. 115-126. New York: Wiley-Liss, 1990.

Journal articles and serial compendia. The complete title, journal, volume number, inclusive pages, and year of publication should be given. Serial compendia, such as *Advances in Cancer Research* and the *Annual Review of Biochemistry*, which appear annually in numbered sequence, should be cited as journals rather than books, thus omitting the names of publishers and editors. *Serial Sources for the BIOSIS Data Base* (Volume 1991) should be consulted for abbreviations of journals and serials.

Books and chapter citations. Citation of a specific chapter or article in a book should carry the author(s) of the chapter, its title, editor(s) of the book, book title, edition, volume, inclusive pages of the chapter, location and name of the publisher, and year of publication. For references to complete books, give all of the above information that is pertinent.

Papers in press and unpublished material. Papers in press may be listed among the references with the journal name and tentative year of publication. Papers in preparation or submitted for publication, unpublished data, and personal communications should be cited in a footnote, not in the Reference section. The names of all authors should be given, along with manuscript titles if possible.

Addenda. Data acquired after acceptance of the paper, by the authors themselves or by others, cannot be added to the text. An addendum may be added in proof upon approval by the Editor-in-Chief. Addenda should be kept extremely brief. The full expense of printing an addendum will be charged to the author.

Tables. Tables should be constructed so that when typeset, they will fit within a single Journal column (8.9 cm or 3½ inches). Tabular material should not duplicate data already presented in the charts. Unnecessary columns of data that can easily be derived from the rest of the results in the table should not be included. Large groups of individual values should be avoided; instead, these should be averaged and an appropriate designation of the dispersion such as standard deviation or standard error included.

Authors are obliged to indicate the significance of their observations by appropriate statistical analysis.

Every table must have a descriptive title and an explanatory paragraph that clearly gives the experimental details for understanding by the reader without reference to the text. Each column must carry an appropriate heading and, if numerical measurements are given, these units should be added to the column heading. Tables should be numbered with Arabic numerals and table footnotes should be indicated with superscript italic letters (^{a,b,c} etc.).

All units of measurement and concentration should be clearly designated. Exponential terminology is discouraged (the term mM is preferable to 10⁻³ M). If exponentials are absolutely unavoidable in column headings, the quantity expressed should be preceded, not followed, by the power of 10 by which its value has been multiplied, i.e., 10⁻³ × concentration (M). This will prevent confusion as to whether the quantity should be multiplied or divided to obtain the correct value.

Illustrations. *Both line-cut (graphs and drawings) and halftone (photographs, photomicrographs, electrophoretic patterns, etc.) illustrations should be designated figures.*

Figures should be used when salient points need illustration for better

comprehension by the reader. Halftones are particularly expensive to reproduce and only those absolutely essential to the clarity of the presentation should be included. Straight-line functions such as relationships between concentration and absorbance, or Lineweaver-Burk plots when these are linear, should be described in a few lines in the text.

Each figure should be labeled in pencil with the first author's name and the figure number on the adhesive label on the reverse side. For halftones, the top of the figure should also be noted.

Legends are required for all figures. They should briefly describe the data shown; details in the text should not be repeated. Staining should be included for halftones, where applicable. Each legend should adequately identify all symbols, abbreviations, mathematical expressions, abscissas, ordinates, units, and reference points used on the figure.

Line-cut illustrations, including flow diagrams and complex biochemical structures, should be prepared with professional instruments (not simply typewritten). They may be on Bristol board, tracing paper or cloth, or coordinate paper printed in light blue. *They should not be mounted on heavy cardboard.* Clear, glossy prints are acceptable in lieu of original drawings, provided that all parts of the illustration are in focus. X-ray films or Polaroid photographs are not acceptable. If original drawings are submitted, they should not be larger than 21.6 × 28 cm (8½ × 11 inches).

Computer-generated graphs are permissible provided that their quality adheres to the same standards as those produced by other means, e.g., all labeling must be clear and scaling must be in the proper proportion to reproduce legibly when reduced.

Except for especially complicated drawings showing large amounts of data, all line-cut illustrations are published at one-column width (8.9 cm or 3½ inches) or less. It is recommended that they be submitted in one-column size. If larger ones are submitted, *it is the responsibility of the author to see that the abscissas, ordinates, lines, and especially the symbols are sufficiently large to permit reduction.* When the graphs are reduced to the size of a single column, the letters and numbers must be at least 1.5 mm high and the smallest part of the illustration must be discernible or the drawing will be returned to the author for correction. On original artwork, this can be accomplished by having the minimum height for lower-case letters 5 mm; numerals and upper-case letters 6 mm; and symbols within the drawings 5 mm. The thickness of ruled lines on graphs is also vital for clear presentation of the data. Size recommendations for lines are as follows: #1 Leroy for graph grids, bonds, and arrows; #2 Leroy for graph borders or reference lines; and #5 Leroy for graph curves or emphasis lines.

The symbols should be defined in the legend. Only those common symbols for which the printer has type (×, ○, ●, □, ■, △, ▲, ○) should be used. Lines connecting the symbols should not extend beyond the data points.

Graphs should be ruled off close to the area occupied by the curve, and abscissas and ordinates should be clearly marked with appropriate units. Explanations of the coordinates should not extend beyond the respective lines. Do not box-in graphs with top and right-hand frame lines unless these are essential for reference. Titles printed outside the confines of the drawing waste space; all of this information should be included in the legend. Also, to conserve space those curves that may appropriately appear together should be included in a single graph.

The use of exponentials for labeling coordinates in graphs is considered ambiguous and should, if possible, be avoided. If exponentials must be used, the quantity expressed should be preceded by the power of 10 by which its value has been multiplied, i.e., 10³ × concentration (M). The form "Concentration (M × 10⁻³)" is not acceptable. If powers of 10 are used, the legend should designate how the quantity is to be calculated (whether multiplied or divided) to give the correct value.

Halftone illustrations should be submitted *unmounted and trimmed* to exclude all but essential material. The set of halftone illustrations intended for the printer's use must be made from original negatives, i.e., they must be first generation glossy prints. Photographs made from other prints are not acceptable for reproduction. Karyotypes should be presented in the form of cardboard plates onto which chromosome sections from an original photomicrograph are pasted.

All halftones will be published at either 1(3½")-, 1½(5")-, or 2(7¼")-column width and placed as close as possible to their first citation in the text. Halftones must be prepared within these dimensions if they are to be reproduced without reduction; otherwise, they will be reduced to conform to these widths.

Figure numbers should not be included on the face of the illustration. However, halftones that must appear together for comparison should be grouped under one figure number with each section lettered "a," "b," "c," etc., in the lower right-hand corner on the face of the illustration. Composite figures may be mounted on a plate, with the sections butted together and tooling (thin white lines) placed between the parts of the

figure. For optimal reproduction, the contrast among photographs on a plate should be consistent. The overall dimensions of photographs on a plate should not exceed 18.4 × 22.4 cm (7¼ × 9 inches). The minimum dimensions to which the plate can be reduced must be indicated on the back.

Symbols, arrows, or letters used in photomicrographs should contrast with the background. India ink lettering is preferred. If pressure-sensitive labeling such as Chartpak, Letraset, or Prestype is used, tissue overlays should be placed on the halftone to prevent the lettering from chipping away. In general, tissue overlays are recommended to protect the surface of halftones. The important areas of the photographs that must be reproduced with greatest fidelity should be indicated on overlays.

Internal scale markers should always be included on the photographs themselves as opposed to listing magnification in the legend since it may be necessary to reduce the figures. Magnifications given in the legend will reflect size before reduction.

Color Photographs. The complete expense of reproducing color photographs will be charged to the author. Estimates for color reproduction can be obtained from the AACR Publications Department. Please be advised that the cost of color reproduction in recent *Cancer Research* articles has ranged from \$875 to \$2400 per page of color. The price is dependent upon such factors as the size and complexity of the illustration; *i.e.*, the smaller and fewer parts to a figure, the less expensive it is to reproduce in color. Thus, if the illustration is a composite figure, the parts should be mounted together in as space-saving an arrangement as possible. *All color illustrations must be submitted on flexible backing, including mounted composite figures.* Please note that the author is responsible for submitting prints that are of sufficient quality to permit accurate reproduction, and for approving the final color proof. *Cancer Research* assumes no responsibility for the quality of the photograph as it appears in the Journal.

ABBREVIATIONS

Abbreviations are in general a hindrance to readers in fields other than that of the author(s), to abstractors, and to scientists in foreign countries. Authors should limit their use to an absolute minimum. Single words should not be abbreviated, *e.g.*, daunomycin, folate, vincristine. Abbreviations are not to be used in titles, but running titles may carry abbreviations for purposes of brevity. Abstracts may contain abbreviations for terms mentioned many times in that section but their identification is mandatory.

Authors should follow the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (*see* section below on **Terminology**). All nonstandard abbreviations should be identified in an inclusive abbreviation footnote to the first such abbreviation after the Abstract.

Abbreviations that form recognizable words, such as EAT and MOPS, are discouraged.

Standard Abbreviations. Authors may use, without definition, the abbreviations in the following lists.

NAD ⁺ , NADH	nicotinamide adenine dinucleotide and its reduced form
NADP ⁺ , NADPH	nicotinamide adenine dinucleotide phosphate and its reduced form
(DPN ⁺ , TPN ⁺ , and their reduced forms are not acceptable.)	
CoA, acyl-CoA	coenzyme A and its acyl derivatives (<i>e.g.</i> , acetyl)
AMP, GMP, IMP, UMP, CMP, TMP	the 5'-phosphates of ribosyladenine, -guanine, -inosine, -uracil, -cytosine, and -thymine
ADP, etc.	the 5'(pyro)-diphosphates of adenosine, etc.
ATP, etc.	the 5'(pyro)-triphosphates of adenosine, etc.
dAMP, dGMP, dIMP	the 5'-phosphates of 2'-deoxyribosyladenine, etc.
RNA, DNA	ribonucleic acid, deoxyribonucleic acid
RNase, DNase	ribonuclease, deoxyribonuclease
mRNA	messenger RNA
nRNA	nuclear RNA
rRNA	ribosomal RNA
tRNA	transfer RNA (sRNA is not recommended for RNA preparations that accept amino acids.)
P _i , PP _i	orthophosphate, pyrophosphate
Tris	tris(hydroxymethyl)methylamine
EDTA	ethylenediaminetetraacetate

POPOP	1,4-bis[2-(5-phenyloxazolyl)]benzene
PPO	2,5-diphenyloxazole
DEAE, TEAE	diethylaminoethyl, triethylaminoethyl
UV, IR	ultraviolet, infrared
RBC, WBC	red blood cell(s), white blood cell(s)

Units of Concentration

molar (moles/liter)	M (not used for moles)
millimolar (millimoles/liter)	mM (preferred to 10 ⁻³ M)
micromolar (micromoles/liter)	μM (preferred to 10 ⁻⁶ M)
nanomolar	nM (not mμM)
picomolar	pM (not μμM)

The expression mg % should be avoided; weight concentrations should be given as g per ml, g per 100 ml, g per liter, etc.

Units of Length, Area, Volume, Mass, Time

The abbreviations below are correct for both singular and plural forms of each term.

meter	m
centimeter	cm
square centimeter	cm ²
millimeter	mm
micrometer (not micron)	μm (not μ)
nanometer (not millimicron)	nm (not mμ)
picometer (not micromicron)	pm (not μμ)
Angstrom (0.1 nm)	Å
liter	not abbreviated
milliliter	ml
microliter	μl (not λ)
gram	g
milligram	mg
microgram	μg (not γ)
kilogram	kg
hour	h
minute	min
second	s

Physical and Chemical Units

retardation factor	R _f
acceleration of gravity	g
sedimentation coefficient	S
sedimentation coefficient in water at 20°	S _{20,w}
degree Celsius (Centigrade)	°C
degree Fahrenheit	°F
Kelvin	K
diffusion coefficient	D
equilibrium constant	K
inhibition constant	K _i
Michaelis constant	K _m
maximum velocity	V _{max}

Others

mole	mol
Curie	Ci
equivalent	eq
counts per minute	cpm
disintegrations per minute	dpm
revolutions per minute	rpm
volt	V
Svedberg unit	S
absorbance	A (not O.D.)
probability	P
roentgen	R
standard deviation	SD
standard error of the mean	SE
logarithm (Briggsian)	log
logarithm (natural)	ln
entropy	S
molecular weight	M _r

In chemical compounds

ortho	o
-------	---

meta	<i>m</i>
para	<i>p</i>
secondary	<i>sec</i>
tertiary	<i>tert</i>

Routes of administration

intramuscular	i.m.
intraperitoneal	i.p.
intravenous	i.v.
oral	p.o.
subcutaneous	s.c.

TERMINOLOGY

Approved terms and abbreviations for chemical substances have been collected in *Biochemical Nomenclature and Related Documents*, International Union of Biochemistry, Third Edition, 1978. This volume is available from: The Biochemical Society, 59 Portland Place, London W1N 3AJ, United Kingdom; FAX: 44-71-323-1136. Included are all recommendations issued by the IUPAC-IUB Commission on Biochemical Nomenclature in the following areas: general abbreviations and symbols; abbreviations and symbols for chemical names of special interest in biological chemistry; stereochemistry; natural products and related compounds; isotopically labeled and modified compounds; biochemical equilibrium data; α -amino acids; symbols for amino acid derivatives and peptides; synthetic modifications of natural peptides; synthetic polypeptides or polymerized amino acids; amino acid sequences; conformation of polypeptide chains; peptide hormones; human immunoglobulins, multiple forms of enzymes; nucleic acids, polynucleotides, and their constituents; lipids; steroids, quinones with isoprenoid side chains; carotenoids; tocopherols and related compounds; carbohydrates; cyclitols; phosphorus-containing compounds of importance in biochemistry; folic acids and related compounds; vitamins B₆ and related compounds; corrinoids.

Isotopically Labeled Compounds. A radioactive nuclide is indicated by its mass number as a superscript to the left of the symbol (³²P); when written out, it should correspond to the spoken word (phosphorus-32).

In an isotopically labeled compound, the isotopic prefix should be placed in *square brackets and immediately precede the name* (word) to which it refers, as in [¹⁴C]thymidine, [α -¹⁴C]leucine, L-[methyl-¹⁴C]methionine, [³H]-3-hydroxykynurenine. When more than one position in a substance is labeled by means of the same isotope and the positions are not indicated, the number of labeled atoms is added as a subscript to the right of the element, as in [¹⁴C]₂glycolic acid. The symbol *U* indicates uniform labeling and *G*, general labeling, e.g., [*U*-¹⁴C]glucose (where the ¹⁴C is uniformly distributed among all six positions) and [*G*-¹⁴C]glucose (where the ¹⁴C is distributed among all six positions, but not necessarily uniformly).

The isotopic prefix precedes that part of the name to which it refers, as in sodium [¹⁴C]formate, iodio[¹⁴C₂]acetic acid, 1-aminio[¹⁴C]methylcyclopentanol, α -naphth[¹⁴C]oic acid, 2-acetamido-7-[¹³¹I]iodo-fluorene, fructose 1,6-[1-³²P]bisphosphate, 17 β -[³H]estradiol. Terms such as "¹³¹I-labeled albumin" should *not* be contracted to "[¹³¹I]albumin" (since native albumin does not contain iodine), and "¹⁴C-labeled amino acids" should similarly *not* be written as "[¹⁴C]amino acids" (since there is no carbon in the amino group).

When isotopes of more than one element are introduced, their symbols should be arranged in alphabetical order, e.g., [3-¹⁴C; 2,3-D; ¹⁵N]serine. Deuterium and tritium may be designated as ²H and ³H or as D and T, respectively.

When not sufficiently distinguished by the foregoing means, the positions of isotopic labeling are indicated by Arabic numerals, Greek letters, or prefixes in italics, as appropriate; these are to be placed within square brackets to appear before the symbol of the element concerned and are attached to it by a hyphen. Examples of this style are [1-¹⁴C]alanine, L-[2-¹⁴C]leucine or L-[α -¹⁴C]leucine, [*carboxy*-¹⁴C]leucine, [2,3-¹⁴C]maleic anhydride, [3,4-¹⁴C, ³⁵S]methionine, L-[methyl-¹⁴C]methionine. The symbol indicating configuration always precedes the bracketed isotope, and a hyphen is used to separate it from the brackets, e.g., D-[¹⁴C]glucose; L-[1-¹⁴C]leucine.

The same rules apply when the labeled compound is designated by a standard abbreviation or symbol other than the atomic symbol, e.g., [α -³²P]ATP, [³²P]CMP, or [¹²⁵I]IdUrd. The square brackets are not to be used, however, with atomic symbols, or when the isotopic symbol is attached to a word that is not a specific chemical name, abbreviation, or symbol. Proper usage here is: ¹⁴CO₂, ²H₂O, H₂³⁵SO₄, ³²P, ¹³¹I-labeled, ³H-ligands, ¹⁴C-steroids.

Enzymes. Authors should use the Recommended Name given in

Enzyme Nomenclature 1984: Recommendations of the Nomenclature Committee of the International Union of Biochemistry on the Nomenclature and Classification of Enzymes (Academic Press, Inc., Orlando, FL, 1984) and "Supplement 1: Corrections and Additions," *Eur. J. Biochem.*, 157: 1-26, 1986. In some cases the Systematic Name or the reaction catalyzed should also be included. It is strongly recommended that the Enzyme Commission number be stated at first mention.

For information on isozyme nomenclature, consult *Biochemical Nomenclature and Related Documents*, mentioned previously.

Histones. The six histone fractions are to be labeled H1, H1*, H2A, H2B, H3, and H4, rather than F1, F1*, F2a2, F2b, F3, and F2a1, respectively.

Interferon Assays. When reporting the calibration of interferon assays, authors should state the name, identifying number, and assigned potency of the international standard used to calibrate their assay, along with the observed geometric mean titer of the standard, the standard deviation of that value, the number of titrations performed to obtain that value, and the technical details of the assay.

Inbred Strains. Designations for inbred mouse strains should conform to the guidelines in "Standardized Nomenclature for Inbred Strains of Mice: Eighth Listing," *Cancer Res.*, 45: 945-977, 1985, prepared by Joan Staats for the Committee on Standardized Nomenclature for Mice; for designations of inbred strains of rats, please refer to "Standardized Nomenclature for Inbred Strains of Rats: Fourth Listing," Michael Festing and Joan Staats. *Transplantation*, 16(No. 3): 221-245, 1973.

Outbred Animal Stocks. Nomenclature for outbred laboratory animals should conform to that recommended by the Committee on Nomenclature, Institute of Laboratory Animal Resources: "A Nomenclature System for Outbred Animals," *Lab. Animal Care*, 20: 903-906, 1970.

Drugs. Generic names of drugs are preferred; a proprietary name may be used only after the first mention of the generic name and should be avoided in titles unless both names can be listed easily. If a foreign proprietary name is used, the name of the comparable U. S. product should be given. When there is no generic name for a drug, authors should give the chemical name or formula or a description of the active ingredients.

Authors should refer to the formally adopted generic names listed in *USAN and the USP Dictionary of Drug Names* (1992).

Tumors. Tumors used in experimental investigations should be clearly described and identified in acceptable terminology. If these tumors are well known and have been identified in previous publications, extended descriptions and photomicrographs are unnecessary.

Authors of clinical papers are encouraged to use the TNM staging system approved by the International Union Against Cancer and the American Joint Committee on Cancer, whenever applicable.

General. The composition of all solutions and buffers should be specified in sufficient detail so that the concentration of each component can be determined. The word "saline" should be replaced by "NaCl solution," along with the exact concentration. Inexact terms such as "physiological saline" or "phosphate-buffered saline" are not permitted; exact contents and concentrations should be given.

Decimals are preferred to fractions; the form 0.01, not .01, is required in text, tables, and illustrations.

Ionic charge should be designated by a superscript immediately following the chemical symbol, e.g., Mg²⁺, S⁻.

POLICY CONCERNING AVAILABILITY OF MATERIALS

It is understood that by publishing any work in *Cancer Research* the authors agree to make freely available to other academic researchers any of the cells, clones of cells or DNA or antibodies, etc. that were used in the research reported and that are not available from commercial suppliers. Also, authors may be required to make primary data available to the Editor-in-Chief in cases of dispute.

TYPESETTING FROM DISKS

To expedite publication, *Cancer Research* is now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to send an electronic disk of the paper along with the required four hard copy printouts. If accepted, the disk, with the printout as backup, will be sent to our printer, Waverly, Inc., where the disk will be converted and the article will then be copyedited on-line and typeset from the disk.

The disk should contain all the parts of the manuscript on **one** file. However, tables and mathematical material, such as equations, may be excluded from the disk file because they must still be copyedited and

typeset in the traditional manner from the accompanying hard copy. The disk will ultimately be returned to the authors.

Please label the outside of the disk with *Cancer Research*, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. In addition, we will need to know the name of the computer used (e.g., IBM/PS2), the name of the operating system and version (e.g., DOS 3.3), and the word processing program and version (e.g., WordPerfect 5.0). Please provide this information to the AACR Publications Department when you send in your disk by filling out and returning the form labeled "Disk Submission Form" that appears after these "Instructions for Authors."

Waverly can convert most commercially available word processing programs. Therefore, even if your program is not listed below, send in your disk with an appropriately completed Disk Submission Form and Waverly will attempt to typeset from it.

Preferred

XyWrite III Plus (for the IBM)
WordPerfect 4.2, 5.0, 5.1 (for the IBM)
WordPerfect (for the Mac)
Microsoft Word (for the IBM)
Microsoft Word Macintosh (Versions 1-4) 400/800K
Wang OIS (WPS)
Wordstar (for the IBM)

Also acceptable

Apple II DOS 3.3
Apple with Appleworks Software
Apple III Plus DOS 3.3
Apple Macintosh 400K Disc/MacWrite 2.2 (text)
Apple Macintosh Plus 800K Disc/MacWrite 4.5 (text)
CPT 8000
DEC WPS-8
DEC Decmate II
DEC Decmate III
Display Write 3
Display Write 4
IBM Displaywriter Word Processor 6580
Lanier Business One Step
Lanier No Problem
Lanier Super No Problem
MASS-11 PC
Multimate
PC Write
PFS Professional Write
Volkswriter 4.0

New releases of word processing software are not always immediately available for conversion. In addition, because of the file structures and internal coding, Waverly cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. They also cannot guarantee that all special characters can be translated. Therefore, the Journal does not assume responsibility for errors in the conversion of newly released software, customized software, or special characters.

Note: It is imperative that the authors ensure that the disk file is the most recent version of the manuscript and that it matches the most recently submitted hard copy.

ALTERATIONS IN PROOF

The Journal provides authors with page proofs for their examination. Extensive alterations in proof lead to sharply increased costs and delays in publication and will necessarily be charged to the authors. We urge our contributors to proofread and edit their manuscripts carefully before submission. The Editors retain the prerogative to question minor stylistic alterations and major alterations that might affect the scientific content of the paper. *Proofs should be returned to the AACR Publications Department within 48 hours of receipt via an overnight delivery service. Proofs not received by the deadline will be published without the authors' corrections.* Authors who will not be available to read their proofs should appoint someone to handle the proofreading of their articles in their absence.

REPRINTS

Reprint order forms are sent to authors along with their proofs. If the form has been omitted inadvertently from the shipment, the AACR Publications Department should be contacted immediately.

Orders are to be placed *prior* to publication according to the schedule

of prices on the form. Reprint order forms should be returned with check or purchase order made payable to Waverly, Inc., 428 E. Preston Street, Baltimore, MD 21202. Requests for additional reprints should also be addressed to Waverly, Inc. For black and white reprint orders placed after the Journal has been released for press but prior to three months after publication, a 25% late fee will be added to the price of the reprints; for orders placed more than three months after publication, there is also an additional fee of \$8.25/page for negatives. The cost of reprints on any late orders for articles that contain *color* must be estimated on an individual basis.

Reprints are shipped approximately 4-6 weeks after publication of the Journal.

It is helpful to the reader if a footnote is included in the paper indicating to which author reprint requests should be addressed.

COPYRIGHT AND PERMISSIONS

Under the copyright law (PL 94-553) which became effective January 1, 1978, copyright for written material is vested in the author from the moment of its creation and remains the property of the author until legally transferred. For this reason it is necessary to require that all authors who wish to publish in *Cancer Research* formally transfer copyright to the proprietor of the Journal, namely, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, and display. However, the Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the Editor-in-Chief. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors *before* corresponding with the Editor-in-Chief.

It is understood in conveying copyright that the authors have not published this material elsewhere, either whole or in part (except in abbreviated form as a preliminary communication), and that they have neither concluded previous negotiations nor initiated pending negotiations for copyright of this material.

When a manuscript has been written by two or more authors, one of them should be designated senior author who will negotiate copyright transfer in the name of all of the authors.

The duly authorized agent of a commercial firm or commissioning organization must sign our copyright transfer form if the author prepared the article as part of his or her official duties as an employee.

The federal government has determined that it has a nonexclusive right to publish or republish material developed from work performed under federal grant-supported projects. Therefore, copyrights for such works are subject to this restriction. Since the federal government does not recognize private copyright for work performed by its employees as part of their official duties, the Journal will accept papers from government laboratories without copyright transfer, provided that the authors abide by the same provisions required of other authors and sign the appropriate section of our copyright transfer form.

Appropriate forms for transfer of copyright will be sent routinely with acknowledgment of receipt of manuscripts. They may also be requested from the AACR Publications Department. *The Journal will not publish a paper unless the form is properly filled out and signed.*

Articles the work and publication of which are subsidized totally by the federal government are understood to be in the public domain and may be copied without restriction or payment of a fee. Copies of the remaining articles in *Cancer Research* may be made for personal or internal use, provided that the copier pay a per-copy fee of \$2.00 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying of journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978. The appearance of a fee code on the back of the title page of each issue indicates that the American Association for Cancer Research, Inc., as copyright owner, has consented to this procedure. [Between June 1978 and August 1983, a fee code appeared on the first page of all articles for which the American Association for Cancer Research, Inc. owned the copyright. For those issues, it is understood that any articles which did not carry this code are in the public domain.]

Those who wish to photocopy articles for which the American Association for Cancer Research, Inc. holds the copyright should report the title of the Journal, the month and year of publication, the initial page number of the article, the number of copies made, and the appropriate

INSTRUCTIONS FOR AUTHORS

fee code to: Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

ADVERTISEMENTS

Advertisement insertion orders and copy must be received 60 days prior to the month of issue in which the advertisement is to be published. The Journal is mailed approximately 5 days before the date of issue; issues are dated the 1st and the 15th of each month. Inquiries regarding advertising should be directed to: Angela Hopkins, Advertising Production Coordinator, Waverly, Inc., 428 E. Preston Street, Baltimore, MD 21202. Telephone: (410) 528-4286.

SUBSCRIPTIONS AND BUSINESS INQUIRIES

Cancer Research is published twice a month, one volume per year, by the American Association for Cancer Research, Inc. Subscriptions include the *Proceedings of the American Association for Cancer Research*, issued in April of each year. Except for members of the Association, all subscriptions are payable in advance to Waverly, Inc., 428 E. Preston Street, Baltimore, MD 21202, to which all business communications,

remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsutsumi Bldg., 13-12, 1-chome, Shimbashi, Minato-ku, Tokyo 105, Japan; Tel. (03)502-6471. The regular annual subscription price of *Cancer Research* for members of the American Association for Cancer Research, Inc., is \$80. Nonmembers of the American Association for Cancer Research within the United States may subscribe to the Journal at a rate of \$350 (individual and institutional) per annual volume, including postage. Institutional and individual nonmembers outside of the United States should add \$60 to their respective rates to offset second-class postage costs. Air mail and other means of delivery are available at extra charge; contact Waverly, Inc. for information.

Changes of address should be sent 60 days in advance and include both old and new addresses. *Member subscribers* should send changes of address to: Member Services, American Association for Cancer Research, Inc., Public Ledger Bldg., 620 Chestnut Street, Suite 816, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: Subscription Fulfillment, Waverly, Inc., 428 E. Preston Street, Baltimore, MD 21202.

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Waverly, Inc., for opinions expressed by the contributors or for the content of advertisements.

AUTHOR INDEX

January 1, 1992

- Abrahams, P. J., 53
 Acs, G., 202
 Adachi, K., 121
 Aigner, K., 108
 Alberg, A. J., 1
 Alderton, P. M., 194
 Allegra, C. J., 36
 Altschuler, E., 209
 Appelbaum, F. R., 89
 Arbeit, J. M., 71
 Badger, C. C., 89
 Baguley, B. C., 209
 Baird, A., 227
 Batova, A., 187
 Batra, J. K., 181
 Beckwith, M., 101
 Beitz, J. G., 227
 Belsler, P., 121
 Bender, H., 121
 Bennett, W. P., 218
 Benson, A. M., 58
 Bernstein, I. D., 89
 Blättler, W. A., 127
 Blumberg, P. M., 202
 Boarman, D. M., 36
 Borek, C., 154
 Bresnick, E., 32
 Broxterman, H. J., 17
 Bunn, P. A., Jr., 24
 Bush, T. L., 1
 Calabresi, P., 227
 Cameron, R., 173
 Cavener, D. R., 77
 Chan, C-L., 32
 Chan, D., 24
 Chang, K., 181
 Chari, R. V. J., 127
 Cheng, J., 222
 Chung, T. D. Y., 231
 Clark, J. W., 227
 Comstock, G. W., 1
 Cook, S. B., 127
 Cornford, E. M., 138
 Creek, K. E., 187
 Croke, S. T., 231
 Curley, T., 64
 Danenberg, K. D., 108
 Danenberg, P. V., 108
 Davol, P., 227
 de Vries, E. G. E., 17
 Dienhart, D. G., 24
 Diez-Itza, I., 95
 Donahue, P. R., 45
 Dorman, T. E., 231
 Dubbelman, T. M. A. R., 117
 Dupont, W. D., 77
 Eary, J. F., 89
 Eastman, A., 32
 Egorin, M. J., 64
 Falls, K. M., 231
 Fang, X-J., 173
 Feller, N., 17
 Fendl, K. C., 235
 Ferrari, S., 11
 Finlay, G. J., 138
 Flowers, M., 173
 Forrest, A., 64
 Frackelton, A. R., Jr., 227
 Friedmann, T., 222
 Frösing, R., 108
 Gibson, N. W., 108
 Goldmacher, V. S., 127
 Gordon, G. B., 1
 Grande, A., 11
 Green, M. D., 194
 Groopman, J. D., 45
 Gross, J., 194
 Gross, J. L., 127
 Gruenstein, E., 144
 Gupta-Burt, S., 149
 Gustavsson, B., 108
 Haas, M., 222
 Harris, C. C., 218
 Hasler, C. M., 202
 Haugen, A., 218
 Helzlsouer, K. J., 1
 Herlyn, D., 121
 Hinds, M., 209
 Hirota, M., 163
 Hodam, J. R., 187
 Holbrook, N. J., 5
 Horikoshi, T., 108
 Hornung, R. L., 101
 Houweling, A., 53
 Iversen, J. M., 64
 Jenkins, G. R., 187
 Jewett, P. B., 24
 Jiaqi, Z., 45
 Jodrell, D. I., 64
 Jun-shi, C., 45
 Karczmar, G. S., 71
 Kato, J., 227
 Katz, D., 149
 Keating, A., 173
 Kerckaert, G., 144
 Koizumi, K., 168
 Krauer, K. G., 132
 Krohn, K. A., 89
 Kuiper, C. M., 17
 Kumble, K. D., 163
 Lankelma, J., 17
 Lappi, D. A., 227
 LeBoeuf, R. A., 144
 Leichman, L., 108
 Liang, S., 121
 Lin, P., 144
 Lisheng, Z., 45
 Litterst, C. L., 149
 Longo, D. L., 101
 Lowenstein, J. M., 154
 López-Otin, C., 95
 Luethy, J. D., 5
 Maehle, L., 218
 Manfredini, R., 11
 Mao, J-i., 231
 Martell, B. A., 127
 Matthews, D. C., 89
 Mayes, J., 209
 McKenzie, I. F. C., 132
 McKenzie, S. J., 127
 Medina, M., 227
 Metcalf, R. A., 218
 Mirabelli, C. K., 231
 Mitchell, M. J., 209
 Ong, A., 154
 Pai, L. H., 181
 Pardridge, W. M., 138
 Parl, F. F., 77
 Pastan, I., 181
 Paxton, J. W., 138
 Pearson, J. W., 101
 Penning, L. C., 117
 Pietersz, G. A., 132
 Pikul, A., 45
 Pinedo, H. M., 17
 Pirisi, L., 187
 Poirier, M. C., 149
 Pour, P. M., 163
 Press, O. W., 89
 Prewett, M., 121
 Prinsze, C., 117
 Przetakiewicz, M., 154
 Ray, M., 108
 Reed, E., 149
 Rigas, B., 84
 Rodeck, U., 121
 Rossi, E., 11
 Ryberg, D., 218
 Sánchez, L. M., 95
 Satitpunwaycha, P., 209
 Scher, H. I., 64
 Schrappe, M., 121
 Shah, S. A., 127
 Shea, L. C. C., 108
 Sherman, M., 173
 Spears, C. P., 108
 Speder, A., 71
 Stadlbauer, T. H. W., 108
 Stanley, J. S., 58
 Sugita, K., 168
 Sutter, A., 121
 Tagawa, M., 24
 Tagliafico, E., 11
 Takahashi, H., 121
 Takahashi, M., 154
 Tan, K. B., 231
 Tolley, R., 24
 Tong, W., 64
 Torelli, G., 11
 Torelli, U., 11
 Toy, B. J., 71
 van der Eb, A. J., 53
 van der Jagt, R. H. C., 89
 VanSteveninck, J., 117
 Versantvoort, C. H. M., 17
 Vishwanatha, J. K., 163
 Vizoso, F., 95
 Volkenandt, M., 108
 Weiner, M. W., 71
 Willingham, M. C., 181
 Wilson, W. R., 138
 Wogan, G. N., 45
 Wong, P. T. T., 84
 Wu, Z., 32
 Yaich, L., 77
 Yeargin, J., 222
 Yee, J-K., 222
 York, J. L., 58
 Yoshida, H., 168
 Young, D., 138
 Zimmnicki, S. J., 235
 Zucchini, P., 11
 Zwelling, L. A., 209

AMERICAN ASSOCIATION FOR CANCER RESEARCH

1992 EMPLOYMENT REGISTER FORMS AND INSTRUCTIONS

INTRODUCTION

The AACR's Employment Register is intended to attract young scientists to the Association, increase interest in AACR programs, and provide a valuable service to all cancer researchers, both senior and junior investigators.

The AACR had operated a limited Employment Register since 1983 with a fee structure that has permitted only the listing of positions and candidates at the annual meeting. Beginning in 1988, AACR Staff scheduled interviews at the annual meeting, and brief advertisements describing available candidates and positions were published in the *Proceedings of the American Association for Cancer Research* and in two issues of *Cancer Research*. These services will be continued in 1992. Registration forms for the 1992 Employment Register can be found on the following pages. Fees have been set at the following levels:

Each candidate registration

- by an AACR member \$10
- by a nonmember \$25

Each position listing

- by an AACR member from a nonprofit or governmental organization \$75
- by a nonmember from a nonprofit or governmental organization \$125
- from a commercial organization \$250

INSTRUCTIONS FOR CANDIDATES

1. Supply all information requested on the attached candidate registration form.
2. Type a short description of your background and the position you are seeking in the 5" X 1 1/4" box provided. Do not include your name; the AACR will assign identification numbers to all candidate listings. Please type carefully; this description will be reproduced as described in the section below entitled PUBLICATION OF LISTINGS.
3. Enclose the original form plus 1 copy.
4. Enclose appropriate payment:
 - a. \$10 from AACR members
 - b. \$25 from nonmembers
5. Checks should be issued in U.S. dollars, drawn on a U.S. bank, and made payable to AACR, Inc.
6. **Forms should be submitted by January 27, 1992**, to ensure publication of listings in the *Proceedings*. However, candidate registration forms will continue to be accepted in the Association Office until April 28, 1992. After that date forms should be submitted at the annual meeting.
7. Mail all candidate registration forms to:
Employment Register
American Association for Cancer Research, Inc.
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

INSTRUCTIONS FOR EMPLOYERS

1. Supply all information requested on the position listing form for each position available.
2. Type a short description of the position available in the 5" X 1 1/4" box provided. Please type carefully; this description will be reproduced as described in the section below entitled PUBLICATION OF LISTINGS.

3. Enclose the original form plus 1 copy.
4. Enclose appropriate payment:
 - a. \$75 from AACR members in nonprofit or governmental organizations,
 - b. \$125 from nonmembers in nonprofit or governmental organizations,
 - c. \$250 from commercial firms.
5. Checks should be issued in U.S. dollars, drawn on a U.S. bank, and made payable to AACR, Inc.
6. **Forms should be submitted by January 27, 1992**, to ensure publication of listings in the *Proceedings*. However, position listing forms will continue to be accepted in the Association Office until April 28, 1992. After that date forms should be submitted at the annual meeting.
7. Mail all position listing forms to:
Employment Register
American Association for Cancer Research, Inc.
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

SCHEDULING OF INTERVIEWS

The AACR will set aside space at the annual meeting for interviews which will be scheduled at mutually agreeable times during the following hours: Wednesday, Thursday, and Friday, May 20-22, from 8:00 a.m. to 5:00 p.m., and Saturday, May 23, from 9:00 a.m. to 12:00 noon. Each candidate and employer will receive an identification number. Registrants who submit their forms and fees by April 28, 1992, will receive an acknowledgment card which contains their identification number.

PUBLICATION OF LISTINGS

Short advertisements describing each candidate and position listing will be published in Volume 33 (1992) of the *Proceedings of the American Association for Cancer Research* and in the September 1, and December 1, 1992, issues of *Cancer Research*. The attached forms contain space for copy for these advertisements. Please type carefully to ensure accurate reproduction of your advertisement. Your copy must not exceed the limits of the box because space for these advertisements is limited. Advertisements for available positions should contain the name and address of the person conducting the job search, and candidates will be able to communicate with that person directly. Candidate advertisements will be anonymous. The AACR will send the candidate's complete form via first-class mail to any registered employer who requests it. The employer must bear the cost of receiving candidate forms in any manner other than first-class mail.

As noted above, because of the early publication date of the *Proceedings*, forms must be received by January 27, 1992, to ensure publication in that document. However, all advertisements submitted before or during the meeting will be published in the two issues of *Cancer Research*. Registrants wishing to withdraw their advertisements must submit written requests to that effect to the Association Office by July 1, 1992, for the September issue, and by October 1, 1992, for the December issue. All participants in the Employment Register are urged to notify the Association immediately of any change in their status so that all listings will remain current.

FURTHER INFORMATION

Questions about the Employment Register may be directed to the Association Office at 215-440-9300.

POSITION LISTING

**AMERICAN ASSOCIATION FOR CANCER RESEARCH
EMPLOYMENT REGISTER**

(Please type and submit original and 1 copy)

DESCRIPTION OF POSITION

Title _____
Nature of Work and Responsibilities (research, teaching, administration, etc.)

Education and Experience Required

Date Position Available _____ Annual Salary Range _____

Location of Position _____

Areas of Specialization
(Indicate a maximum of three in order of greatest activity)

- _____ ¹Biochemistry & Biophysics _____ ²Biostatistics _____ ³Carcinogenesis _____ ⁴Cellular Biology & Genetics
- _____ ⁵Clinical Investigations _____ ⁶Endocrinology _____ ⁷Epidemiology _____ ⁸Immunology
- _____ ⁹Molecular Biology & Genetics _____ ¹⁰Preclinical Pharmacology & Experimental Therapeutics _____ ¹¹Virology
- _____ ¹²Other: _____
(please specify)

=====

EMPLOYER'S REPRESENTATIVE(S)

Name(s) and Title(s) _____ ACR Member Number _____

Institution _____

Address _____

Telephone _____

AVAILABILITY FOR INTERVIEWS AT AACR ANNUAL MEETING

I ___ plan ___ do not plan to attend the AACR Annual Meeting in San Diego.
Dates available for interviews: ___ May 20 ___ May 21 ___ May 22 ___ May 23

=====

ADVERTISEMENT (Please type a short description of the position in the box below. If received by January 27, 1992, your advertisement will be printed in the 1992 *Proceedings*. All advertisements will appear in the September 1, and December 1, 1992, issues of *Cancer Research*.)

SAMPLE: Asst. Prof. (tenure track) in Mol. Biol. Postdoc. and teaching exp. Conduct independent res. on oncogenes, chimeric antibodies, and mol. biol. of tumor antigens. Limited medical/grad. teaching. Avail. Sept. 1992. \$30,000-\$35,000. Contact Dr. A. C. Brown, Dept. of Mol. Biol., Smith Univ., Chicago, NY.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

INFORMATION ON APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR) is a scientific society consisting of laboratory and clinical cancer researchers. It was founded in 1907 "to bring together active investigators of the cancer problem for presentation and discussion of new or significant observations; and to foster research in cancer and other phenomena of growth." Members of the AACR enjoy the following benefits:

1. subscriptions to the journals *Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at the reduced member rate;
2. the privilege of sponsoring an abstract for presentation at the AACR annual meeting;
3. an advance copy of the Program and *Proceedings* pertaining to each annual meeting;
4. a reduced registration rate at all scientific meetings;
5. early notification of events in the AACR's series of special conferences;
6. subscriptions to any future AACR journals at reduced member rates;
7. reduced rates for the AACR Employment Register;
8. the benefit of AACR's public education activities;
9. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas, and who have conducted two years of meritorious research that has resulted in publications relevant to cancer. If a candidate is working in a research area not directly related to the cancer field but has conducted research of exceptional scientific merit, he or she may also qualify for membership.

Corresponding membership is open to qualified persons who are not residents of the Americas. The requirements for corresponding membership are the same as those for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin soon after submitting their applications should apply for corresponding membership. All other individuals should apply for active membership and transfer to corresponding status at a later date if they should leave the Americas.

PROCEDURES FOR APPLICATION

There are three deadlines for receipt of a membership application: March 1, July 1, and October 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application in AACR Office	Notification of Candidate
March 1	May
July 1	September
October 1	December

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical standards.—OR—The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter).—OR—The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building
620 Chestnut St.
Suite 816
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues, a major portion of which is designated for a subscription to at least one of the AACR's publications. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rate will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

All corresponding members elected after May 23, 1985, are required to pay an annual assessment in lieu of dues. This assessment, which is equivalent to that portion of the regular dues that pertains to support of activities other than publications, is imposed to defray the cost of sending AACR publications to members outside the Americas. Corresponding members may, if they wish, subscribe to *Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the reduced member rate.

Applicants elected in May will be responsible for payment of that year's dues; applicants elected in September and December will pay dues in the following year. Applicants elected in May and September will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in December.

Margaret Foti
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building
620 Chestnut St.
Suite 816
Philadelphia, PA 19106



APPLICATION FOR MEMBERSHIP

CATEGORY OF MEMBERSHIP: Active Corresponding

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____

PRESENT POSITION/TITLE: _____

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)
TELEPHONE NUMBER: _____
FAX NUMBER: _____

PRIMARY FIELD OF RESEARCH (Please check only one):

____ Biochemistry and Biophysics ____ Biostatistics ____ Carcinogenesis
____ Cellular Biology and Genetics ____ Clinical Investigations ____ Endocrinology
____ Epidemiology ____ Immunology ____ Molecular Biology and Genetics
____ Preclinical Pharmacology and Experimental Therapeutics
____ Virology ____ Other: _____
(Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts.)

CANDIDATE NOMINATED BY: _____ (Please type or print)
CANDIDATE SECONDED BY: _____ (Please type or print)

STATEMENT OF SUPPORT (in place of letters of recommendation)

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? ____ years

Will the candidate make a long-term contribution to cancer research? ____ Yes ____ No

Does the candidate's research adhere to accepted ethical standards? ____ Yes ____ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

How long has the candidate worked in the field of cancer research? ____ years

Will the candidate make a long-term contribution to cancer research? ____ Yes ____ No

Does the candidate's research adhere to accepted ethical standards? ____ Yes ____ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator * _____ Date _____ Signature of seconder _____ Date _____

See Guidelines for Application on the reverse side of this form for further instructions.

* Nominators must be active, emeritus, or honorary members of the AACR.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who live in the Americas and who are following a course of study or who are working in a research program relevant to cancer.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 "to bring together active investigators of the cancer problem for presentation and discussion of new or significant observations; and to foster research in cancer and other phenomena of growth." Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring an abstract for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the abstract and (b) an active member in good standing of the AACR also signs the abstract in support of the work (In this instance, the active member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the Program and (if one has been purchased by the associate member) the *Proceedings of the American Association for Cancer Research* which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the journals *Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at the reduced member rate;
6. subscriptions to any future AACR journals at reduced member rates;
7. early notification of events in the AACR's new series of small scientific meetings on timely scientific topics;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the active member nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check in the amount of \$20, which represents one year's dues payment, must accompany the application. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the \$20 dues payment to:

American Association for Cancer Research
Public Ledger Building
620 Chestnut St.
Suite 816
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1992 have been set at \$20 per year. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in December 1991 for the forthcoming annual meeting must have paid dues for 1991. Any newly elected associate members of the AACR who have already purchased subscriptions to *Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance on or before January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1991 may retain associate membership until December 31, 1995. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti,
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building
620 Chestnut St.
Suite 816
Philadelphia, PA 19106



APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Postal Code) (Country)

TELEPHONE NUMBER: _____

FAX NUMBER: _____

PRESENT ACADEMIC STATUS/TITLE (Please check only one):

Graduate Student Medical Student
 Physician in Training Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

Biochemistry and Biophysics Biostatistics Carcinogenesis
 Cellular Biology and Genetics Clinical Investigations Endocrinology
 Epidemiology Immunology Molecular Biology and Genetics
 Preclinical Pharmacology and Experimental Therapeutics
 Virology Other: _____

(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY: _____

(Please type or print name of AACR active member in good standing.)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: _____ Date: _____

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator: _____ Date: _____

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check for \$20 in U.S. funds made payable to AACR, Inc. and drawn on a U.S. bank. Check *one* of the following boxes *only* if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the
 current forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in May of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

(This form may be reproduced.)

AMERICAN ASSOCIATION FOR CANCER RESEARCH EIGHTY-THIRD ANNUAL MEETING

May 20-23, 1992
San Diego Convention Center
San Diego, California

ADVANCE REGISTRATION FORM

(Please print or type)

NAME: _____
Last Name First Name/Middle Initial AACR Member Number

TITLE: _____ ADDRESS: _____
Institution

Street, Building, or Post Office Box

City State or Province Zip/Postal Code Country (if not U.S.)

TELEPHONE: _____ FAX: _____

Check this box if you have a physical disability and special requirements for transportation, hotel accommodations, or other facilities connected with the meeting. A member of the Association Staff will contact you.

WHAT IS YOUR PRIMARY FIELD OF RESEARCH (Please check only one):

- ¹Biochemistry and Biophysics ²Biostatistics ³Carcinogenesis ⁴Cellular Biology & Genetics ⁵Clinical Investigations
 ⁶Endocrinology ⁷Epidemiology ⁸Immunology ⁹Molecular Biology
 ¹⁰Preclinical Pharmacology & Experimental Therapeutics ¹¹Virology ¹²Other (please specify): _____

ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1992 AACR MEETING? Yes No

ON WHICH DAYS WILL YOU ATTEND THE 1992 AACR ANNUAL MEETING?

- Wednesday, May 20 Thursday, May 21 Friday, May 22 Saturday, May 23

WILL YOU ATTEND THE ASCO MEETING IN SAN DIEGO? Yes No

ON WHICH DAYS WILL YOU ATTEND THE 1992 ASCO ANNUAL MEETING?

- Sunday, May 17 Monday, May 18 Tuesday, May 19

PAYMENT OF REGISTRATION

Fees may be paid by check or with a MasterCard, VISA, American Express, or Eurocard account. All payments must be made in U.S. currency, and all checks must be drawn on a U.S. bank. Payment must accompany this form; purchase orders will not be accepted as payment. Honorary and emeritus members may register gratis.

FEES	On or Before Mar. 30	After Mar. 30	METHOD OF PAYMENT
<input type="checkbox"/> Active/Corresponding Member Rate	\$ 80	\$100	<input type="checkbox"/> Check payable to AACR, Inc. in U.S. currency, drawn on a U.S. bank
<input type="checkbox"/> Honorary/Emeritus Member Rate	\$ 0	\$ 0	
<input type="checkbox"/> Nonmember Rate (includes a copy of AACR <i>Proceedings</i>)	\$150	\$170	_____ <small>Person/Institution Issuing Check Check No.</small>
<input type="checkbox"/> Associate Member/Student Rate* (does not include a copy of AACR <i>Proceedings</i>)	\$ 35	\$ 40	<input type="checkbox"/> MasterCard <input type="checkbox"/> VISA <input type="checkbox"/> American Express <input type="checkbox"/> Eurocard
<input type="checkbox"/> AACR <i>Proceedings</i> *	\$ 25	\$ 25	_____ <small>Account Number and Expiration Date</small>
<input type="checkbox"/> Overseas Airmail Surcharge [†]	\$ 22	N/A	
<input type="checkbox"/> Workshop Application (additional form required)	\$ 50	\$ 50	
Total Enclosed or Charged	_____	_____	_____ <small>Signature</small>

THE DEADLINE FOR REDUCED REGISTRATION FEES IS MARCH 30, 1992. Registration by mail will be accepted until April 30. Registration will also be possible at the San Diego Convention Center from May 19-23.

*Students must enclose a statement, signed by the registrar, dean, or department head of their university or college on official letterhead, confirming their status. **Postdoctoral fellows or physicians in training do not qualify for the student registration rate unless they are associate members of the AACR.** An application for associate membership may accompany this form, but these should be submitted well before the March 30 deadline as review of the associate membership application may delay registration.

*AACR members with paid-up subscriptions to an AACR journal and registrants who pay the nonmember fee receive the *Proceedings* automatically. If these members or nonmembers check this box and pay the \$25 fee, they will receive an additional copy of the *Proceedings*.

[†]Optional payment for registrants outside of the U.S. and Canada only. Registrants paying this surcharge will receive meeting publications via air mailed matter before the annual meeting.

Mail all advance registration forms with applicable fees to Annual Meeting Registration, American Association for Cancer Research, Inc., Public Ledger Building, 620 Chestnut Street, Suite 816, Philadelphia, PA 19106-3483. FAX: 215-440-9313. Badges and receipts will be sent to you in April or early May. AACR members in good standing will receive copies of the Program and *Proceedings* prior to the meeting. Nonmember and student registrants who meet the March 30 deadline will also receive the Program and (if they have purchased it) the *Proceedings* prior to the meeting. Nonmembers and students who do not meet the deadline must pick up publications at the meeting site.

REFUND POLICY


Refunds on registration fees will be granted on written request received in the AACR Office by May 13, 1992. Requests received after this date will not be honored. Receipts and badges (if they have been mailed) must be returned to the AACR Office with the refund request. A cancellation fee of \$25 will be deducted from all refunds to cover administrative costs.

(This form may be reproduced.)

Keep up
with the latest developments in

Cancer Research

**The Official Journal of the
American Association for Cancer Research**



Carlo M. Croce, M.D., Editor-in-Chief

Subscribe to Cancer Research—the leading citation source of original studies in cancer research and cancer-related biomedical science. Issued semimonthly, *Cancer Research* publishes 7,000 pages of important research each year, including the following regular features:

- **The most up-to-date articles** in basic research and clinical and epidemiological investigations by authors from the United States and more than 20 countries
- **Perspectives in Cancer Research**, in which leading investigators explore contemporary and at times controversial topics
- **Advances in Brief**, a rapid communication category for short but definitive, highly significant reports
- **Supplemental Issues** developed from symposia on relevant subjects
- **Proceedings of the American Association for Cancer Research**, a special annual issue that offers stimulating new research ideas in abstract form

**Order
Now!**

Yes, I want to keep up with the latest developments in *Cancer Research*. Enter my one-year subscription.

1992 Subscription Rates:

Individual \$350 Institutional \$350

Add \$60 for delivery outside the U.S. Subscriptions payable in advance (in US currency or equivalent) to:

WAVERLY PRESS, INC. / CANCER RESEARCH
428 East Preston Street / Baltimore, MD 21202

NAME _____

INSTITUTION _____

ADDRESS _____

CITY / STATE / ZIP _____

Allow 8 weeks for receipt of first issue.

**Cancer
Research**
The Most
Highly Cited
Journal
In Its Field

**Guidelines for Submitting Disks
to
American Association for Cancer Research Publications**

The word processing packages that we prefer are as follows:

XyWrite III Plus (for the IBM)	Microsoft Word (for the IBM)
WordPerfect 4.2, 5.0, 5.1 (for the IBM)	Wang OIS (WPS)
Wordstar (for the IBM)	

Also acceptable:

Apple II DOS 3.3	Display Write 4
Apple with Appleworks Software	IBM Displaywriter Word Processor 6580
Apple III Plus DOS 3.3	Lanier Business One Step
Apple Macintosh 400K Disc/ MacWrite 2.2 (text)	Lanier No Problem
Apple Macintosh Plus 800K Disc/ MacWrite 4.5 (text)	Lanier Super No Problem
CPT 8000	MASS-11 PC
DEC WPS-8	Microsoft Word Macintosh (Versions 1-4) 400/800K
DEC Decmate II	Multimate
DEC Decmate III	PC Write
Display Write 3	PFS Professional Write
	Volkswriter 4.0
	Wordstar 2000

New releases of word processing software are not always immediately available for conversion. In addition, because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK.
DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.



DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. Authors are encouraged to submit electronic disks of their manuscripts along with the typed manuscript. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

Name used to access paper on disk: _____

Name of computer used (e.g., IBM/PS2): _____

Operating system and version (e.g., DOS 3.3): _____

Word processing program and version (e.g., WordPerfect 5.0): _____

[See reverse for acceptable programs.]

Manuscript number (if known): _____

First author: _____

Corresponding author (if different from first author): _____

Telephone/FAX numbers: _____

This form (both sides) may be reproduced.



AACR SPECIAL CONFERENCES IN CANCER RESEARCH: 1992-1993

FEBRUARY 10-14, 1992

Molecular Oncology as a Basis for New Strategies in Cancer Therapy

Second Joint Conference with the Japanese Cancer Association

Co-Chairpersons: I. Bernard Weinstein, New York, NY; Susumu Nishimura, Tokyo, Japan

Sheraton Waikiki Hotel, Honolulu, HI

SEPTEMBER 23-26, 1992

Biochemical and Molecular Analytical Methods Applicable to Cancer Epidemiology (Tentative Title)

Chairperson: David Schottenfeld, Ann Arbor, MI

The Registry Resort, Naples, FL

OCTOBER 18-22, 1992

Cell Cycle Control and Growth Regulation (Tentative Title)

Chairperson: Arnold J. Levine, Princeton, NJ
Program Committee: Edward Harlow, Charlestown, MA; Peter M. Howley, Bethesda, MD; David M. Livingston, Boston, MA

Chatham Bars Inn, Chatham (Cape Cod), MA

NOVEMBER 4-8, 1992

Differentiation and Cancer (Tentative Title)

Co-Chairpersons: Webster K. Cavenee, San Diego, CA; Raymond L. White, Salt Lake City, UT

Marriott Hilton Head Resort, Hilton Head, SC

DECEMBER 7-12, 1992

Molecular Aspects of Chemical Carcinogenesis (Tentative Title)

Chairperson: Lawrence A. Loeb, Seattle, WA
Banff Springs Hotel, Banff, Alberta, Canada

FEBRUARY 1-6, 1993

Cancer and Development (Tentative Title)

Chairperson: Carlo M. Croce, Philadelphia, PA
Big Sky Resort, Big Sky, MT

MARCH 15-20, 1993

Mechanism of Action of Retinoids, Vitamin D, and Steroid Hormones

Co-Chairpersons: Michael B. Sporn, Bethesda, MD; Ronald M. Evans, San Diego, CA; David Mangelsdorf, San Diego, CA

Banff Centre, Banff, Alberta, Canada

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)

Communication Between Cells



A cytotoxic T-lymphocyte adheres to two tumor cells.

The contact mechanisms between white blood cells and their different targets, play a central role in the course of an immune reaction. The adhesion molecules, responsible mediators of short term cell contacts, play a major role in the course of different kinds of inflammatory reactions.

BioSource International offers an extensive line of MAbs, ELISA kits, and cytokines for the study of cellular adhesion and communication.

ELISA Kits

- ICAM-1*
- TNF- α
- TNF- β *
- sTNF-R*
- IL-8/NAP-1*
- IL-6

Monoclonal Antibodies Against

- | | | | |
|-----------|---------|----------|-------------|
| • CD9 | • CD36 | • CDw49b | • CD56 |
| • CD11-a* | • CD41 | • CDw49c | • CD61 |
| • CD11-b* | • CD41b | • CDw49e | • CD62 |
| • CD11-c | • CD42a | • CDw49p | • CD63 |
| • CD18* | • CD42b | • CD51 | • gp-90 MEL |
| • CD29 | • CD44 | • CD54* | • ELAM-1 |



BIOSOURCE
INTERNATIONAL

Please contact BioSource for our 1992 catalog and a FREE copy of *Communication Between Cells* by Bender Med Systems.

(800) 242-0607



Bender MedSystems